Expert Perspectives: CDK 4/6 Inhibitor Therapy for ER+ Metastatic Breast Cancer

This Expert Perspectives activity features the clinical faculty from a symposium held at the 2016 Annual Meeting of the Oncology Nursing Society sharing highlights from the symposium and additional relevant clinical commentary.

Significant advances have elevated breast cancer care to new levels of success and complexity. In particular, for women with estrogen receptor-positive (ER+) metastatic breast cancer (MBC), the availability of cyclin-dependent kinase 4 and 6 (CDK 4/6) inhibitor therapy is a notable recent advance. As such, clinicians who treat breast cancer need ongoing education on this topic to ensure safe and effective use of this therapy.

This content was originally published on Imedex.

Stay in the know.
OncNet Newsletter